Patents Examined by Gary Counts
  • Patent number: 11231373
    Abstract: A method according to one or more aspects may be a method of measuring a detection material contained in a sample by using a cartridge including: chambers each capable of housing at least one of the detection material and a reagent; and a path through which the detection material is transferred between the chambers. The method may include: moving at least one of the chambers and the path to a measurement position and an image capturing range by rotating the cartridge about a rotational shaft; measuring the detection material in the measurement position; and capturing an image of a monitoring target comprising at least one of the chambers and the path in the image capturing range.
    Type: Grant
    Filed: November 28, 2018
    Date of Patent: January 25, 2022
    Inventors: Tomoyuki Nose, Yusuke Muda, Kanako Nagaoka, Noriyuki Narisada, Varun Nambigari
  • Patent number: 11215623
    Abstract: Methods and kits for detecting antibodies (e.g., anti-drug antibodies). Such methods and kits permit the detection of, for example, anti-drug antibodies in human body fluids, such as blood, plasma and serum.
    Type: Grant
    Filed: August 8, 2017
    Date of Patent: January 4, 2022
    Inventors: Ryan Grabert, Susan Richards, Valerie Theobald, Yuanxin Xu, Jad Zoghbi
  • Patent number: 11204354
    Abstract: Kits and methods to distinguish between false and true labor are provided. The kits and methods can utilize differences in abundance and/or differences in the rate of change in abundance of B7-H2, SORC2, TF, C1-Esterase Inhibitor, Ran, IMD-H1 and/or PGAM1, as markers of true labor.
    Type: Grant
    Filed: November 7, 2016
    Date of Patent: December 21, 2021
    Assignees: Wayne State University, The United States of America, as Represented by the Secretary, Dept. of Health and Human Services
    Inventors: Adi L. Tarca, Piya Chaemsaithong, Tinnakorn Chaiworapongsa, Sonia S. Hassan, Roberto Romero
  • Patent number: 11181538
    Abstract: Diagnosing an oxidative stress (OS) in companion animals comprises screening a bodily fluid sample to detect the presence of an OS biomarker, selectively isoprostane and antioxidants, HODE, microRNAs, TAC, GSH, MDA, and TNF-alpha. The sample can be saliva.
    Type: Grant
    Filed: March 19, 2021
    Date of Patent: November 23, 2021
    Assignee: HEMOPET
    Inventors: Winifred Jean Dodds, Denis Marc Callewaert
  • Patent number: 11169153
    Abstract: Herein disclosed is a method for the normalization of an immunological test, characterized in that the presence of a comparable amount of cells is determined by a sandwich ELISA test in which the capture antibody includes at least one antibody that binds to at least one keratin selected from among keratin 4, 5, 6, 8, 10, 13 and 18 and the detection antibody includes at least one antibody that binds to the selected keratin.
    Type: Grant
    Filed: July 28, 2016
    Date of Patent: November 9, 2021
    Assignee: Mikrogen GmbH
    Inventors: Isabel Koch, Oliver Boecher, Erwin Soutschek, Steven McNamara
  • Patent number: 11137407
    Abstract: The invention provides a method of diagnosing arthritis or other joint degrading disease in a subject which comprises determining whether there is a presence or increase of lubricin having a joint tissue posttranslational modification, in a blood sample from the subject, the presence or increase of the lubricin having the joint tissue posttranslational modification indicating arthritis or other joint degrading disease in the subject. The invention further provides a kit or protocol for detecting arthritis or other joint degrading disease by detecting lubricin, the lubricin comprising a joint tissue posttranslational modification.
    Type: Grant
    Filed: February 23, 2017
    Date of Patent: October 5, 2021
    Assignee: Lynxon AB
    Inventors: Niclas Karlsson, Chunsheng Jin, Sebastian Kalamajski, Sarah Ann Flowers
  • Patent number: 11137408
    Abstract: The present disclosure provided methods for determining the severity of glaucoma using the expression levels of GDF15. Determining the severity of glaucoma aids in treatment decisions.
    Type: Grant
    Filed: January 30, 2017
    Date of Patent: October 5, 2021
    Assignee: Washington University
    Inventors: Rajendra S. Apte, Jun Yoshino
  • Patent number: 11131676
    Abstract: The present invention provides a method of using increased levels of one or more biomarkers to identify subjects having non-celiac gluten sensitivity or non-celiac wheat sensitivity. The identification would aid the physician or health professional to determine a specific treatment for the patient, for example, a diet that eliminates wheat, rye, and/or barley. In one embodiment, the biomarkers are one or more of soluble CD 14 (sCD14), lipopolysaccharide-binding protein (LBP), anti-lipopolysaccharide antibodies, anti-flagellin antibodies, anti-gliadin antibodies, and intestinal fatty acid-binding protein (FABP2). The present invention also provides a method of using the same markers to monitor the response to treatment for non-celiac wheat sensitivity in a subject.
    Type: Grant
    Filed: February 24, 2017
    Date of Patent: September 28, 2021
    Inventor: Armin Alaedini
  • Patent number: 11119014
    Abstract: A method and apparatus for the rapid and reliable preparation of a sample for use in testing for target analytes such as bacteria, viruses, toxins and pathogenic agents in various products. A sample for testing the target analyte is collected from various sources. The method for sample preparation provides for an express process for preparing collected samples for testing. The collected sample may be concentrated by centrifugation, filtration, or other means suitable for sample concentration, homogenized with the addition of a broth and enriched for specified period of time. Immunomagnetic separation of the sample occurs with receptor-coated magnetic microspheres in different test-specific formulations (singleplex or multiplex). An automatic testing system is disclosed which includes a biological testing cassette, in which testing of the sample occurs using liquid crystal diagnostic methodologies.
    Type: Grant
    Filed: June 4, 2018
    Date of Patent: September 14, 2021
    Assignee: Pathogen Systems, Inc.
    Inventors: Curtis Hubert Stumpf, Weidong Zhao
  • Patent number: 11112414
    Abstract: The invention is a method for treating a heart failure patient with the steps of measuring the concentration of IGFBP2 in a blood, plasma or urine sample obtained from the heart failure patient and comparing the patient's IGFBP2 level to a threshold value derived from IGFBP2 measured in samples taken from a group of patients with heart failure selected from the group consisting of stage I, stage stage III and stage IV heart failure, according to New York Heart Association (NYHA) classification system. A patient with an IGFBP2 level that exceeds the threshold value is admitted or readmitted to a hospital and treated with at least one treatment selected from the group consisting of administration of a beta-blocker, an angiotensin-converting enzyme inhibitor, an angiotensin receptor blocker, an aldosterone antagonist, an implantable cardiac defibrillator, a cardiac resynchronization therapy, an implantable left ventricular assist device and a heart transplant.
    Type: Grant
    Filed: June 6, 2014
    Date of Patent: September 7, 2021
    Inventors: Philippe Rouet, Fatima Smith-Rouet, Franck Desmoulin, Michel Galinier
  • Patent number: 11105815
    Abstract: Methods for determining the presence of pathologic amylin in a subject with diabetes or pre-diabetes are provided herein. The method includes obtaining a skin sample from a subject and determining if there is pathologic amylin present in the skin sample.
    Type: Grant
    Filed: April 26, 2019
    Date of Patent: August 31, 2021
    Assignee: University of Kentucky Research Foundation
    Inventors: Larry B. Goldstein, Florin Despa
  • Patent number: 11105817
    Abstract: Provided herein are methods and markers for diagnosing cardiovascular disease and/or neurodegenearative diseases in a subject. The methods include obtaining a biological sample from a subject in need of diagnosis and detecting the amount of a citrullinated protein or a citrullinated peptide in the biological sample obtained from said subject.
    Type: Grant
    Filed: June 20, 2016
    Date of Patent: August 31, 2021
    Assignee: Cedars-Sinai Medical Center
    Inventors: Jennifer Van Eyk, Justyna Fert-Bober, Erin Crowgey, Ronald Holewinski, Benjamin Phillip Berman
  • Patent number: 11099187
    Abstract: A determination method for determining, in an immunodepressed subject, a humoral response due to the presence of a target infectious agent, by detection, in a biological sample of the subject, of at least one target antibody that is susceptible of being produced by the subject when the latter is infected with or has been infected with the target infectious agent. Also, a determination method for determining a humoral response due to the presence of a target infectious agent from a biological sample from an immunodepressed or non-immunodepressed subject, in which the dilution ratio of the sample is selected as a function of the immunodepressed condition or otherwise of the subject concerned.
    Type: Grant
    Filed: January 12, 2017
    Date of Patent: August 24, 2021
    Assignee: BIOMÉRIEUX
    Inventor: Ghislaine Bouchard
  • Patent number: 11092610
    Abstract: A biomarker and a technology for utilizing the same, of the present invention, can be useful in the early diagnosis, in urine, of a renal function abnormality due to diabetes and drugs and in the prediction and evaluation of disease severity, and, further, can accurately determine, with high sensitivity and specificity, a renal function abnormality due to diabetes and exposure to drugs, and enable the early and effective diagnosis of kidney abnormality symptoms through a relatively simple method, thereby being widely usable in various fields, such as in clinical experiments essential for new drug development and in diagnosing drug-causing acute/chronic renal failure, which can frequently occur in the clinical treatment process.
    Type: Grant
    Filed: August 16, 2017
    Date of Patent: August 17, 2021
    Inventors: Byung Mu Lee, Hyung Sik Kim, Kyeong Seok Kim, Ji Yeon Son
  • Patent number: 11090310
    Abstract: This application describes novel therapeutic strategies for treating patients with hypertriglyceridemia and/or chylomicronemia based on the presence of GPIHBP1 autoantibodies. It was unexpectedly found that autoantibodies to GPIHBP1, a GPI anchored protein of capillary endothelial cells that shuttles lipoprotein lipase to its site of action in the capillary lumen, were found to be present in patients with hypertriglyceridemia, and that the autoantibodies blocked the binding of lipoprotein lipase (LPL) to GPIHBP1. Patients having hypertriglyceridemia and/or chylomicronemia and also having GPIHBP1 autoantibodies may be treated with a therapeutically effective amount of an immunosuppressive treatment and/or GPIHBP1 activator.
    Type: Grant
    Filed: July 28, 2017
    Date of Patent: August 17, 2021
    Assignee: The Regents of the University of California
    Inventors: Kazuya Miyashita, Stephen G. Young, Anne P. Beigneux, Loren G. Fong, Katsuyuki Nakajima
  • Patent number: 11085922
    Abstract: A method for detecting and quantifying anti-neutrophil-cytoplasmic antibodies (ANCA) in a sample of bodily fluid from a patient suspected of suffering from an autoimmune disease, including the steps of contacting human polymorphonuclear neutrophils able to release extracellular traps (NETs) with microspheres to produce NET-coated microspheres, contacting the NET-coated microspheres with the sample of bodily fluid, and labeling and subsequent analyzing of anti-neutrophil-cytoplasmic antibodies by flow cytometric methods.
    Type: Grant
    Filed: December 13, 2018
    Date of Patent: August 10, 2021
    Assignee: Immundiagnostik AG
    Inventors: Franz Paul Armbruster, Moritz Leppkes
  • Patent number: 11079373
    Abstract: Aspects of the present disclosure include methods that include co-culturing a cell and a microparticle that includes a capture ligand, in a culture medium under conditions in which a biomarker produced by the cell is bound by the capture ligand. Such methods may further include detecting (e.g., by flow or mass cytometry) complexes that include the microparticle, the capture ligand, the biomarker, and a detection reagent. The methods may further include determining the proportion or number of cells among a heterogeneous cell population that produced the biomarker and/or the level of biomarker secreted by such cells. Compositions, systems and kits are also provided.
    Type: Grant
    Filed: November 26, 2019
    Date of Patent: August 3, 2021
    Assignee: The Board of Trustees of the Leland Stanford Junior University
    Inventors: Dolly B. Tyan, Ge Chen
  • Patent number: 11079395
    Abstract: Provided herein are methods for predicting or determining whether a subject with coronary artery disease is likely to experience or develop a major adverse cardiovascular event (MACE) based on determining cardiac troponin (cTnI) levels in a human at rest and during or after exercise.
    Type: Grant
    Filed: February 28, 2020
    Date of Patent: August 3, 2021
    Assignees: Abbott Laboratories, Emory University
    Inventors: Agim Beshiri, Arshed A. Quyyumi
  • Patent number: 11067579
    Abstract: A novel serological target marker GP73 used for diagnosing and identifying a simple fatty liver and steatohepatitis in populations with fatty liver and a detection application method thereof. The serological target marker GP73 and the application thereof can replace golden standard liver puncture to identify and diagnose the simple fatty liver and steatohepatitis in populations with fatty liver, reduce the detection pain of a patient, and have an extremely high clinical application value in clinically identifying and diagnosing the simple fatty liver and steatohepatitis in the populations with fatty liver and assisting the treatment of the simple fatty liver and steatohepatitis.
    Type: Grant
    Filed: June 19, 2017
    Date of Patent: July 20, 2021
    Inventors: Hongshan Wei, Boan Li, Changqing Lin, Yong Qiao
  • Patent number: 11067586
    Abstract: Subject of the present invention is an in vitro method for therapy follow-up in septic patients wherein the concentration of mature ADM 1-52 and/or mature ADM 1-52-Gly in a sample of bodily fluid of said septic patient is determined using an assay comprising two binders that bind to two different regions within the region of mature adrenomedullin and/or adrenomedullin-Gly that is aminoacid 21-52-amid SEQ ID No. 1 or aminoacid 21-52-Gly SEQ ID No. 2 wherein each of said regions comprises at least 4 or 5 amino acids. The invention further relates to assays and calibration methods.
    Type: Grant
    Filed: November 7, 2016
    Date of Patent: July 20, 2021
    Inventor: Andreas Bergmann